Report from the extraordinary general meeting of Cereno Scientific AB (publ)
Today, September 14, 2023, Cereno Scientific AB (publ) held an extraordinary general meeting at MAQS Advokatbyrå's premises at Östra Hamngatan 24 in Gothenburg. Chairman of the general meeting was Attorney Dag Fredlund from MAQS Advokatbyrå.
The following main resolutions were resolved at the general meeting:
Resolution on a directed issue of warrants to employees
The general meeting resolved to adopt the Board of Directors proposal to issue warrants, with deviation from the shareholders' preferential rights, to the company with the right and obligation to transfer warrants to current and future employees of the company.
The board's complete proposal is available on the company's website (www.cerenoscientific.com).
Resolution on a directed issue of warrants to selected members of the Board of Directors
The general meeting resolved to adopt the shareholders' proposal on a directed issue of warrants with deviation from the shareholders' preferential rights to selected members of the company's Board of Directors.
The complete proposal is available on the company's website (www.cerenoscientific.com).
For further information, please contact:
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, ﬁbrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.